This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kalli, K. R. Articles by Knutson, K. L. Search for Related Content PubMed PubMed Citation Articles by Kalli, K. R. Articles by Knutson, K. L.

An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with Cancer

Departments of ¹ Oncology, ² Immunology, and ³ Health Sciences Research, Mayo Clinic, Rochester, Minnesota; ⁴ Tumor Vaccine Group, Center for Translational Medicine in Women's Health, Seattle, Washington; and ⁵ Pharmexa-Epimmune, Inc., San Diego, California

Requests for reprints: Keith L. Knutson, College of Medicine, Mayo Clinic, 342C Guggenheim, 200 First Street Southwest, Mayo Clinic, Rochester, MN 55905. Phone: 507-284-0545; Fax: 507-266-0981; E-mail: knutson.keith{at}mayo.edu.

Key Words: MHC class II • HLA-DR • Helper T cells • Vaccines • Peptides

Recent studies have shown the importance of helper CD4 T cells in initiating and sustaining tumor-specific CD8 T-cell immunity. This has paved the way for identifying MHC class II epitopes that could be incorporated into class I–based vaccines. In this study, the goal was to identify an HLA-DR–degenerate epitope pool derived from insulin-like growth factor binding protein 2 (IGFBP-2). IGFBP-2, a regulator of insulin-like growth factor action, is overexpressed in the majority of breast and ovarian cancers. Using algorithms, we predicted 29 HLA-DR1–binding epitopes. Binding assays targeting 15 different HLA-DRs revealed that 10 epitopes were degenerate, binding to at least four different HLA-DR variants. An IFN- enzyme-linked immunosorbent spot assay was used to assess immunity to these 10 epitopes in 48 patients with either breast or ovarian cancer and 18 controls. Elevated T-cell immunity in patients was detected in 4 of the 10 epitopes (IGFBP2.17, IGFBP2.22, IGFBP2.249, and IGFBP2.293). The cumulative T-cell frequency of these four epitopes was elevated in patients relative to controls. All four peptides are naturally processed and presented to CD4 T-cells. The degenerate pool of peptides covers nearly 80% of patients and may be useful for augmenting CD4 T-cell immunity in patients undergoing immunization. [Cancer Res 2008;68(12):4893–901]